Clinical Trials
4 trialsNCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02706626 2023-01-26
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Criterium, Inc.
Phase 2 Terminated
NCT04634110 2022-10-24
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Phase 2 Terminated
NCT04005144 2022-10-17
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Phase 1 Terminated